Publications by authors named "Anna-Luisa Thiepold"
Article Synopsis
- Glioblastomas grow quickly and often create areas with low oxygen (hypoxia) and cell death; EGFR and mTORC1 signaling play key roles in this process and are potential targets for treatment.
- Research shows that inhibiting EGFR and mTORC1 can have negative effects under tumor conditions, while activating mTORC1 by suppressing its inhibitor TSC2 makes glioma cells more sensitive to cell death caused by low oxygen.
- This study found that mTORC1 activation leads to increased oxygen consumption and changes in metabolic pathways, suggesting it might help identify glioblastoma patients who could benefit from therapies that induce hypoxia, like bevacizumab.
The value of bevacizumab (BEV) in recurrent glioblastoma is unclear. Imaging parameters and progression-free survival (PFS) are problematic endpoints. Few data exist on clinical factors influencing overall survival (OS) in unselected patients with recurrent glioblastoma exposed to BEV.
View Article and Find Full Text PDFBackground: Current pathological diagnostics include the analysis of (epi-)genetic alterations as well as oncogenic pathways. Deregulated mammalian target of rapamycin complex 1 (mTORC1) signaling has been implicated in a variety of cancers including malignant gliomas and is considered a promising target in cancer treatment. Monitoring of mTORC1 activity before and during inhibitor therapy is essential.
View Article and Find Full Text PDFBackground: Hypoxia is a key driver for infiltrative growth in experimental gliomas. It has remained elusive whether tumor hypoxia in glioblastoma patients contributes to distant or diffuse recurrences. We therefore investigated the influence of perioperative cerebral ischemia on patterns of progression in glioblastoma patients.
View Article and Find Full Text PDFB10 is a glycosylated derivative of betulinic acid with promising activity against glioma cells. Lysosomal cell death pathways appear to be essential for its cytotoxicity. We investigated the influence of hypoxia, nutrient deprivation and current standard therapies on B10 cytotoxicity.
View Article and Find Full Text PDFStudy Objective: As chemotherapy with teniposide and a nitrosourea is commonly used for the treatment of patients with recurrent glioma but can be associated with severe myelotoxicity, we sought to determine if prophylactic administration of pegfilgrastim could reduce leukopenia or infectious complications in patients receiving this chemotherapeutic regimen.
Design: Retrospective medical record review.
Setting: University-affiliated neurooncology hospital in Frankfurt, Germany.